- Home
- ACRS vs HQI Comparison
ACRS vs HQI Comparison
Compare ACRS & HQI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- HQI
- Stock Information
- Founded
- ACRS 2012
- HQI 2002
- Country
- ACRS United States
- HQI United States
- Employees
- ACRS N/A
- HQI N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- HQI Professional Services
- Sector
- ACRS Health Care
- HQI Consumer Discretionary
- Exchange
- ACRS Nasdaq
- HQI Nasdaq
- Market Cap
- ACRS 127.6M
- HQI 147.0M
- IPO Year
- ACRS 2015
- HQI N/A
- Fundamental
- Price
- ACRS $1.26
- HQI $9.94
- Analyst Decision
- ACRS Strong Buy
- HQI Strong Buy
- Analyst Count
- ACRS 7
- HQI 2
- Target Price
- ACRS $10.67
- HQI $17.50
- AVG Volume (30 Days)
- ACRS 801.8K
- HQI 15.6K
- Earning Date
- ACRS 05-08-2025
- HQI 05-08-2025
- Dividend Yield
- ACRS N/A
- HQI 2.43%
- EPS Growth
- ACRS N/A
- HQI N/A
- EPS
- ACRS N/A
- HQI 0.24
- Revenue
- ACRS $17,777,000.00
- HQI $33,651,000.00
- Revenue This Year
- ACRS N/A
- HQI $1.90
- Revenue Next Year
- ACRS $425.96
- HQI $5.26
- P/E Ratio
- ACRS N/A
- HQI $40.77
- Revenue Growth
- ACRS N/A
- HQI N/A
- 52 Week Low
- ACRS $0.95
- HQI $9.98
- 52 Week High
- ACRS $5.17
- HQI $15.75
- Technical
- Relative Strength Index (RSI)
- ACRS 43.64
- HQI 33.81
- Support Level
- ACRS $1.20
- HQI $10.02
- Resistance Level
- ACRS $1.46
- HQI $10.46
- Average True Range (ATR)
- ACRS 0.11
- HQI 0.42
- MACD
- ACRS 0.02
- HQI 0.07
- Stochastic Oscillator
- ACRS 41.77
- HQI 45.45
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About HQI HireQuest Inc. (DE)
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.